ES2705043T3 - Criopreservación de sustitutos de piel humana viables - Google Patents
Criopreservación de sustitutos de piel humana viables Download PDFInfo
- Publication number
- ES2705043T3 ES2705043T3 ES14775892T ES14775892T ES2705043T3 ES 2705043 T3 ES2705043 T3 ES 2705043T3 ES 14775892 T ES14775892 T ES 14775892T ES 14775892 T ES14775892 T ES 14775892T ES 2705043 T3 ES2705043 T3 ES 2705043T3
- Authority
- ES
- Spain
- Prior art keywords
- skin
- equivalent
- skin equivalent
- cryopreserved
- tissues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 48
- 210000001519 tissue Anatomy 0.000 claims abstract description 222
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 146
- 238000000034 method Methods 0.000 claims abstract description 80
- 239000002577 cryoprotective agent Substances 0.000 claims abstract description 59
- 239000000243 solution Substances 0.000 claims abstract description 59
- 239000008150 cryoprotective solution Substances 0.000 claims abstract description 42
- 238000007710 freezing Methods 0.000 claims abstract description 39
- 230000008014 freezing Effects 0.000 claims abstract description 38
- 230000002500 effect on skin Effects 0.000 claims abstract description 21
- 238000004806 packaging method and process Methods 0.000 claims abstract description 14
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 13
- 210000000981 epithelium Anatomy 0.000 claims abstract description 7
- 210000003491 skin Anatomy 0.000 claims description 203
- 210000004027 cell Anatomy 0.000 claims description 113
- 210000002510 keratinocyte Anatomy 0.000 claims description 67
- 230000035899 viability Effects 0.000 claims description 51
- 238000010257 thawing Methods 0.000 claims description 38
- 239000002609 medium Substances 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 32
- 206010052428 Wound Diseases 0.000 claims description 29
- 208000027418 Wounds and injury Diseases 0.000 claims description 29
- 239000001963 growth medium Substances 0.000 claims description 20
- 239000002250 absorbent Substances 0.000 claims description 17
- 230000002745 absorbent Effects 0.000 claims description 17
- 238000009792 diffusion process Methods 0.000 claims description 14
- 238000000134 MTT assay Methods 0.000 claims description 13
- 231100000002 MTT assay Toxicity 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 210000004379 membrane Anatomy 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 2
- 210000005127 stratified epithelium Anatomy 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 description 47
- 238000011534 incubation Methods 0.000 description 33
- 238000003860 storage Methods 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000010410 layer Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000004744 fabric Substances 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- 239000007995 HEPES buffer Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 7
- 235000011089 carbon dioxide Nutrition 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229920002799 BoPET Polymers 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000005041 Mylar™ Substances 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000000959 cryoprotective effect Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 101001093139 Homo sapiens MAU2 chromatid cohesion factor homolog Proteins 0.000 description 4
- 102100036309 MAU2 chromatid cohesion factor homolog Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010072170 Skin wound Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 230000001023 pro-angiogenic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 102000014509 cathelicidin Human genes 0.000 description 3
- 108060001132 cathelicidin Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000301 hemidesmosome Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 239000012808 vapor phase Substances 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 2
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 2
- 108010001781 Apligraf Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 210000001047 desmosome Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000009516 primary packaging Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100026887 Beta-defensin 103 Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 210000000661 isochromosome Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000012961 medicinal therapy Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000009581 negative-pressure wound therapy Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779661P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/025599 WO2014160000A1 (en) | 2013-03-13 | 2014-03-13 | Cryopreservation of viable human skin substitutes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2705043T3 true ES2705043T3 (es) | 2019-03-21 |
Family
ID=51527939
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14775892T Active ES2705043T3 (es) | 2013-03-13 | 2014-03-13 | Criopreservación de sustitutos de piel humana viables |
| ES18197432T Active ES2893844T3 (es) | 2013-03-13 | 2014-03-13 | Criopreservación de sustitutos de piel humana viables |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18197432T Active ES2893844T3 (es) | 2013-03-13 | 2014-03-13 | Criopreservación de sustitutos de piel humana viables |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10091983B2 (OSRAM) |
| EP (3) | EP3900534A1 (OSRAM) |
| JP (2) | JP6580028B2 (OSRAM) |
| AU (4) | AU2014244264B2 (OSRAM) |
| CA (2) | CA2905656C (OSRAM) |
| DK (2) | DK2967836T3 (OSRAM) |
| ES (2) | ES2705043T3 (OSRAM) |
| IL (1) | IL241448B (OSRAM) |
| PT (2) | PT3470018T (OSRAM) |
| WO (1) | WO2014160000A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2905656C (en) * | 2013-03-13 | 2020-04-14 | Stratatech Corporation | Cryopreservation of viable human skin substitutes |
| HRP20201663T1 (hr) * | 2014-07-09 | 2020-12-25 | F. Hoffmann - La Roche Ag | PRILAGOĐAVANJE pH VRIJEDNOSTI RADI POBOLJŠANJA OPORAVKA BANAKA STANICA USLIJED ODMRZAVANJA |
| WO2016149254A1 (en) | 2015-03-17 | 2016-09-22 | Chimera Bioengineering, Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| US11052111B2 (en) * | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| US10222369B2 (en) | 2016-05-17 | 2019-03-05 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| JP7045378B2 (ja) | 2016-09-01 | 2022-03-31 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｇｏｌｄ最適化ＣＡＲ Ｔ細胞 |
| JP2021518747A (ja) | 2018-02-13 | 2021-08-05 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｒｎａ不安定化エレメントを使用した遺伝子発現の調整 |
| EP3843798A1 (en) | 2018-08-31 | 2021-07-07 | Wisconsin Alumni Research Foundation | Generating arterial endothelial cell-seeded vascular grafts |
| AU2019385712B2 (en) * | 2018-11-22 | 2025-10-02 | Vitrafy Life Sciences Limited | Method and apparatus for freezing of biological products |
| WO2021034653A1 (en) | 2019-08-18 | 2021-02-25 | Chimera Bioengineering, Inc. | Combination therapy with gold controlled transgenes |
| US20220347353A1 (en) * | 2019-09-27 | 2022-11-03 | Stratatech Corporation | Methods for treating acute wounds and improving outcomes |
| CN114836291B (zh) * | 2021-02-01 | 2025-11-21 | 深圳拜尔洛克生物技术有限公司 | 生物材料解冻复苏的系统及其方法 |
| AU2022282461A1 (en) * | 2021-05-28 | 2023-11-16 | Stratatech Corporation | Tissue container systems |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485096A (en) | 1982-02-26 | 1984-11-27 | Massachusetts Institute Of Technology | Tissue-equivalent and method for preparation thereof |
| IL95429A (en) | 1989-09-15 | 1997-09-30 | Organogenesis | Living tissue equivalents comprising hydrated collagen lattice and a collagen gel and their production |
| ATE161408T1 (de) | 1990-04-24 | 1998-01-15 | Mark Eisenberg | Zusammengesetztes äquivalent der lebenden haut |
| IT1248934B (it) | 1990-06-01 | 1995-02-11 | Fidia Spa | Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle |
| US5145770A (en) * | 1990-06-04 | 1992-09-08 | Biosurface Technology, Inc. | Cryopreservation of cultured epithelial sheets |
| US5518878A (en) * | 1993-09-15 | 1996-05-21 | Organogenesis Inc. | Cryopreservation of cultured skin or cornea equivalents with agitation |
| US5891617A (en) | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
| JPH10509610A (ja) * | 1994-11-09 | 1998-09-22 | クリ・ハークチ，ワリド | 創傷修復用包帯およびそれらの保存法 |
| IT1281870B1 (it) * | 1995-04-27 | 1998-03-03 | Fidia Advanced Biopolymers Srl | Pelle artificiale umana costituita da materiali biocompatibili a base di derivati dell'acido ialuronico |
| US5693332C1 (en) | 1995-08-11 | 2001-01-09 | Univ California | Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure |
| US5689961A (en) * | 1996-01-30 | 1997-11-25 | Organogenesis Inc. | Ice seeding apparatus for cryopreservation systems |
| US5968546A (en) | 1997-05-16 | 1999-10-19 | Baur; Marcus | Keratinocyte culture from precursor cells |
| US5989837A (en) | 1998-07-13 | 1999-11-23 | Wisconsin Alumni Research Foundation | Immortalized human keratinocyte cell line |
| EP1389078A4 (en) * | 2000-12-27 | 2004-03-17 | Ortec International Inc | METHOD FOR THE PRODUCTION OF CRYCONSERVED COMPOSED LIVING CONSTRUCTS AND PRODUCTS PRODUCED FROM THEM |
| US6974697B2 (en) | 2001-03-02 | 2005-12-13 | Stratech Corporation | Skin substitutes with improved barrier function |
| NZ549526A (en) | 2001-03-02 | 2009-06-26 | Stratatech Corp | Human skin equivalents comprising near diploid immortalized keratinocyte cells (NIKS) |
| JP4753577B2 (ja) | 2002-04-30 | 2011-08-24 | ストラタテック コーポレーション | 外因性血管新生増殖因子を発現するケラチノサイト |
| AU2003254298A1 (en) | 2002-08-02 | 2004-02-23 | Stratatech Corporation | Species specific dna detection |
| CA2527822A1 (en) * | 2003-05-30 | 2004-12-23 | Stratatech Corporation | Room temperature storage of organs |
| US7674291B2 (en) | 2003-08-01 | 2010-03-09 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
| WO2005041880A2 (en) * | 2003-10-29 | 2005-05-12 | Science & Technology Corporation @ Unm | RhPV AS A MODEL FOR HPV-INDUCED CANCERS |
| CA2600177C (en) | 2005-03-01 | 2011-06-14 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
| CA2601595C (en) | 2005-03-17 | 2015-02-24 | Stratatech Corporation | Skin substitutes with improved purity |
| KR100803384B1 (ko) | 2007-01-15 | 2008-02-13 | 한스바이오메드 주식회사 | 피부조직의 장기 보관 방법 |
| NO2215212T3 (OSRAM) * | 2007-11-14 | 2018-01-27 | ||
| PT2352472T (pt) | 2008-11-04 | 2017-04-11 | Stratatech Corp | Equivalentes de pele secos e irradiados prontos a utilizar |
| WO2010135655A2 (en) | 2009-05-21 | 2010-11-25 | Stratatech Corporation | Human skin substitutes expressing il-12 |
| US20130108683A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating partial and full thickness wounds and injuries |
| WO2013062994A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating full thickness burn injuries |
| CA2905656C (en) * | 2013-03-13 | 2020-04-14 | Stratatech Corporation | Cryopreservation of viable human skin substitutes |
-
2014
- 2014-03-13 CA CA2905656A patent/CA2905656C/en active Active
- 2014-03-13 AU AU2014244264A patent/AU2014244264B2/en not_active Ceased
- 2014-03-13 CA CA3071928A patent/CA3071928A1/en active Pending
- 2014-03-13 US US14/208,439 patent/US10091983B2/en active Active
- 2014-03-13 DK DK14775892.4T patent/DK2967836T3/en active
- 2014-03-13 EP EP21177142.3A patent/EP3900534A1/en not_active Withdrawn
- 2014-03-13 ES ES14775892T patent/ES2705043T3/es active Active
- 2014-03-13 DK DK18197432.0T patent/DK3470018T3/da active
- 2014-03-13 EP EP18197432.0A patent/EP3470018B1/en active Active
- 2014-03-13 PT PT18197432T patent/PT3470018T/pt unknown
- 2014-03-13 EP EP14775892.4A patent/EP2967836B1/en active Active
- 2014-03-13 WO PCT/US2014/025599 patent/WO2014160000A1/en not_active Ceased
- 2014-03-13 JP JP2016501891A patent/JP6580028B2/ja active Active
- 2014-03-13 PT PT14775892T patent/PT2967836T/pt unknown
- 2014-03-13 ES ES18197432T patent/ES2893844T3/es active Active
-
2015
- 2015-09-10 IL IL241448A patent/IL241448B/en active IP Right Grant
-
2017
- 2017-07-17 AU AU2017206148A patent/AU2017206148B2/en not_active Ceased
-
2018
- 2018-09-05 US US16/122,598 patent/US11297829B2/en active Active
-
2019
- 2019-08-27 JP JP2019154515A patent/JP7220640B2/ja active Active
- 2019-09-17 AU AU2019232795A patent/AU2019232795B2/en not_active Ceased
-
2021
- 2021-11-05 AU AU2021261937A patent/AU2021261937B2/en not_active Ceased
-
2022
- 2022-03-14 US US17/694,245 patent/US20220192181A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2705043T3 (es) | Criopreservación de sustitutos de piel humana viables | |
| US20220330542A1 (en) | Tissue container systems | |
| ES2621324T3 (es) | Equivalentes de piel secos e irradiados listos para su uso | |
| HK40059784A (en) | Method for warming cryoconserved human skin substitutes | |
| US20220287298A1 (en) | Tissue container systems | |
| JP2024519818A (ja) | 組織容器システム | |
| NZ796375A (en) | Tissue container systems |